Outcome of Board Meeting for Approval of Audited Financials for the year ended 31st March,2025

Emphasis of matterProfit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

—Next day

₹41.55

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%—

Pharmaceuticals peers, median of 148sector-0.0%—

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—-0.1—+0.1—

Next day

—+0.2—-0.0—

—+0.6—+0.8—

—+0.9—+0.3—

+0.0+1.0-1.0+0.0+0.0

—+0.7—-0.7—

—+1.8—+0.0—

15d

—+1.7—-0.8—

—+3.1—-0.7—

-9.6+1.7-11.3+0.6-10.2

—-1.0—-3.0—

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma's board, meeting on May 26, 2025, approved audited financial results for FY25. The company reported zero revenue from operations, with all income classified as 'other income' of Rs. 66.14 lakhs (up from Rs. 13.05 lakhs in FY24). Profit after tax swung from a loss of Rs. 5.91 lakhs to a profit of Rs. 40.41 lakhs, and EPS improved from Rs. (0.10) to Rs. 0.69. The balance sheet changed dramatically: total assets jumped from Rs. 132.61 lakhs to Rs. 2,560.02 lakhs, driven mainly by a surge in investments (Rs. 61 lakhs to Rs. 2,135 lakhs) and cash (Rs. 4.15 lakhs to Rs. 285.73 lakhs). This followed a preferential share allotment of Rs. 276 lakhs that more than doubled the equity share capital to Rs. 1,397 lakhs. The statutory auditor issued an unmodified opinion but flagged an Emphasis of Matter regarding loans and advances given to various parties whose confirmation and recoverability could not be verified.

Likely market impact

The company has no active pharma operations, so the 'turnaround to profit' is driven entirely by investment income, not business activity – shareholders should watch whether the company eventually restarts operations. The auditor's Emphasis of Matter on unrecoverable loans is a yellow flag. The large capital infusion and shift to an investment-heavy balance sheet change the company's risk profile significantly.